BC
ADMA icon

Bayforest Capital’s ADMA Biologics ADMA Stock Holding History

Bayforest Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.6K Buy
+954
New +$15.1K 0.01% 808

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bayforest Capital's ADMA Position: Q1 2026 in Review

Bayforest Capital opened a new position in ADMA Biologics (ADMA) in Q1 2026: 954 shares worth $8.6K. The stake represents 0.01% of the portfolio and ranks #808 among its holdings.

356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Bayforest Capital held 954 shares of ADMA Biologics worth $8.6K as of Q1 2026.
  • ADMA Biologics was a new Bayforest Capital position in Q1 2026.
  • ADMA Biologics made up 0.01% of Bayforest Capital's portfolio in Q1 2026, its #808 holding.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Bayforest Capital's 13F filing for Q1 2026, filed 15 Apr 2026.